News

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...
Fierce Biotech1d
Gilead lays off 36 people after axing California expansion plan
Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...
BioSpace7d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
FirstCuriosity on MSN2d
Gilead Falls: How The Testaments Ends the Tyranny of The Handmaid’s Tale
Margaret Atwood’s chilling world of Gilead returns in The Testaments, the long-anticipated sequel to her groundbreaking novel The Handmaid’s Tale. This short dives into the heart of the dystopia, ...
US FDA pauses Gilead trials testing experimental HIV pill combination
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
Fierce Biotech8d
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.